HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

regimen over a period of 48 weeks. Results from the SOLO trial were presented in November 2002 at the 6th International Congress on Drug Therapy in HIV Infection in Glasgow, United Kingdom.

NEAT was a phase III, randomized, open-label, parallel-group 48-week study that compared 908 BID and nelfinavir BID, both in combination with ABC and 3TC in 249 antiretroviral therapy-nave patients. The primary endpoint of the NEAT study was the proportion of subjects with vRNA <400 c/mL at 24 and 48 weeks. Interim 24-week data from NEAT were presented in September at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICACC) in San Diego, and 48-week data are being presented here today.

Once approved, GSK will market 908 and GSK and Vertex will co-promote it in the United States and key markets in Europe.

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and an industry leader in HIV research and therapies. The company is engaged in basic research programs designed to investigate new targets to treat HIV.

This press release may contain forward-looking statements, including that 48-week interim analysis of the NEAT and SOLO studies in GlaxoSmithKline's pivotal program for 908 is indicative of a promising clinical and commercial outlook for 908, once approved. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause Vertex's actual results to vary materially. These risks and uncertainties include, among other things, the risk that approval will be delayed or will not be obtained, that 908 will not be commercially successful, and those other risks listed under Risk Factors in Vertex's form 10-K filed with the Securities and Exchange Commission on April 1, 2002.


'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
(Date:1/15/2014)... Hills, IL (PRWEB) January 15, 2014 ... to find hard-working items for the lab, from fluid ... as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model for ...
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
Cached News: